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Abstract
Objective: To evaluate the association of cord blood magnesium concentrations at the time of birth with
cerebral palsy (CP) and neonatal death.
Study Design: A secondary analysis of a randomized controlled trial that randomized women at imminent
risk of delivery between 24 and 31 weeks of gestation to receive magnesium sulfate or placebo. This
‘study’s primary outcome was a composite of either moderate to severe CP or death. Secondary outcomes
included CP, moderate to severe CP, neonatal death, and neonatal head ultrasound findings. We used a
logistic regression model to evaluate the relationship between the concentration of magnesium in cord
blood and study outcomes.
Results: A total of 668 women were included in this analysis and were randomized to magnesium sulfate
at 28 ± 2.5 ‘weeks’ gestation. Cord blood magnesium concentrations were not associated with the
primary outcome of infant death by 1 year of age or moderate or severe cerebral palsy, as assessed at or
beyond 2 years of age (aOR 0.95 (0.67, 1.36), p = 0.79). Cord blood magnesium concentrations were not
associated with any of the secondary outcome measurements.
Conclusion: Cord blood magnesium concentrations were not associated with moderate to severe cerebral
palsy or death, or other neurodevelopmental or sonographic outcomes.

Introduction
Cerebral palsy (CP) is a group of permanent disorders of the development of movement and posture
attributed to non-progressive disturbances, which have occurred in the developing fetal or infant brain.
These motor disorders are often accompanied by epilepsy and changes in sensation, perception,
cognition, and behavior [1]. Recently, Maenner et al. [2] analyzed the results of two U.S. representative
surveys and found the prevalence of CP to be in the range of 2.6 to 2.9 per 1,000 children. Those born
before 28 weeks of gestation have a significantly higher prevalence ranging from 40 to 100 per 1,000 live
births [1].
In the past 30 years, several studies were conducted to evaluate the role of magnesium sulfate therapy
for fetal neuroprotection among women at risk of preterm birth [3–6], with the two most extensive
randomized controlled trials (RCTs) showing significant reduction in moderate to severe cerebral palsy
among surviving children who were exposed to magnesium sulfate in-utero [4, 6]. Subsequently, multiple
meta-analyses found a significant decrease in the risk of cerebral palsy with the antenatal use of
magnesium sulfate [3, 7, 8]. In 2010, the American College of Obstetricians and Gynecologists (ACOG)
and the Society for Maternal-Fetal Medicine (SMFM) published a statement “that magnesium sulfate
given before anticipated early preterm birth reduces the risk of cerebral palsy in surviving infants.” For
those electing to use magnesium sulfate, ACOG, and SMFM recommended developing specific guidelines
for use in accordance with one of the more sizeable trials [9].

Page 2/11

While physicians and hospitals created protocols and treatment guidelines for the use of magnesium
sulfate for fetal neuroprotection, controversies remain. Experts argue that none of the large RCTs found
any difference in the rate of the primary outcome (which in many cases was a composite of death or CP)
[10, 11]. There was controversy regarding the optimal dose and timing of treatment. Trials included a
range of dosing schedules with loading doses ranging from 4–6 g of intravenous magnesium sulfate
and maintenance dosing ranging from nothing to 2 g/hr [8]. There is not enough evidence to recommend
an optimum dosing scheme, and the Cochrane meta-analysis did not find one dosing regimen superior to
another [9, 12, 13]. Moreover, a sequential trial analysis and a 6-year follow up of the Australasian
Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) trial do not support the use of magnesium
sulfate for neuroprotection [14, 15].
With these controversies, we sought to determine if the fetal neuroprotection of antenatal magnesium
sulfate may be demonstrated by investigating the association between cord blood magnesium
concentrations at the time of birth and cerebral palsy. Within the obstetric community, there is a lack of
consensus related to magnesium sulfate infusion at the time of delivery or magnesium cord blood
concentrations. So, this study aimed to undertake secondary data analysis to investigate the
reproducibility of the association between women exposed to magnesium sulfate in utero and the lack of
association with CP or death in infants.

Methods
This is a secondary analysis of data from the Eunice Kennedy Shriver National Institutes of Child Health
and Human Development Maternal-Fetal Medicine Units (NICHD-MFMU) Network multicenter randomized
trial (Beneficial Effects of Antenatal Magnesium [BEAM]). This analysis was exempt from review by the
Institutional Review Board, as it met the criteria of research involving the study of existing data.
Women at imminent risk of delivery before 32 weeks of gestation were assigned to receive magnesium
sulfate or placebo [6]. A total of 2,241 women were recruited from December 1997 to May 2004 at 20
clinical centers in the U.S. They were randomized to receive magnesium sulfate or placebo when they
were in between their 24th and 31st completed weeks of pregnancy. The recruitment and study protocol
were presented in detail in the original publication of the randomized trial [6]. Briefly, women were eligible
for inclusion if they were carrying singletons or twins and were at elevated risk for preterm delivery
because of rupture of membranes, advanced preterm dilation (4 to 8 cm), or a planned preterm delivery
[6]. Magnesium sulfate was given intravenously as a 6 g loading dose (over 20 to 30 minutes) followed
by a 2 g per hour maintenance infusion and stopped after 12 hours if delivery was no longer imminent.
The maintenance infusion (2 g per hour) was restarted when delivery was determined to be imminent
again, and if it had been at least 6 hours, another loading dose (6 g) was given [6].
Women enrolled in the primary trial, who received magnesium sulfate within 6 hours of delivery, were
included in the current analysis if cord blood magnesium concentration was available. Our primary
outcome was defined as a composite of infant death by 1 year of age or moderate or severe cerebral
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palsy, as assessed at or beyond 2 years of age [6]. Cerebral palsy was diagnosed by a certified
pediatrician or pediatric neurologist, blinded to the maternal assignment. The Gross Motor Function
Classification System was used to assess the severity of cerebral palsy. Details of the diagnostic criteria
for cerebral palsy used in the parent study can be found in the initial publication [6]. Secondary outcomes
included any cerebral palsy at two years of age, moderate to severe cerebral palsy, neonatal death, and
neonatal neurosonographic abnormalities defined as either intraventricular hemorrhage, severe
intraventricular hemorrhage (grade 3 and 4), or periventricular leukomalacia.
Statistical analyses were performed using SAS Enterprise Guide 9.4 (SAS Institute Inc., Cary, NC).
Descriptive demographic and baseline characteristics of the study population were reported. To explore
the association between cord blood magnesium concentration and neonatal/child outcomes, logistic
regression analyses were performed. The addition of covariates followed a stepwise pattern guided by
the reduction of cost function > 3.83. Clustering was adjusted for twin gestation. Convergence was
reached in all model runs. Gestational age at delivery and infant gender were included in the final model.
Missing data were excluded from analyses. Significance was defined as two-sided P < 0.05.

Results
Out of 2,241 women in the original study, 668 (30%) received magnesium sulfate within six hours of
delivery. Table 1 presents the demographic and obstetric characteristics of the study population. The
mean (± SDD) maternal age and gestational age at randomization were 26 (± 5.8) years old and 28 (±
2.5) weeks of gestation, respectively. A total of 261 (39%) women were nulliparous, and 64 (10%) had
twin gestations.
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Table 1
Maternal characteristics of the study population
Characteristics

Population (n = 668)

Twin gestation

64 (10)

Married

328 (49)

Race/ethnicity
African American
Caucasian
Hispanic
Asian
Native American/Other

296 (44)
243 (36)
111 (17)
7 (1)
11 (2)

Nulliparous

261 (39)

Previous preterm delivery

174 (26)

No prenatal care

39 (6)

Smoking during pregnancy

188 (28)

Alcohol use during pregnancy

55 (8)

Illicit substance use during pregnancy

70 (11)

Previous preterm delivery

160 (24)

Age (years)

26 ± 5.8

Pre-pregnancy BMI (kg/m2)

26 ± 6.7

Gestational age at randomization (weeks)

28 ± 2.5

Education level (years)

12 ± 2.5

Cervical dilation (cm)

1.6 ± 1.9

Time since rupture (hours)

101.6 (28.9–242.1)

BMI = body mass index
Data are reported as mean ± standard deviation, median (interquartile range) or n (%).
The mean time from magnesium dose initiation until birth was 0.13 ± 0.60 hours (Table 2). The mean ±
SD cord blood magnesium concentration was 2.98 ± 0.81 meq/L (Table 2). While studies regarding
reference ranges for cord blood magnesium concentrations in preterm infants are limited, the normal
reference range reported is from 1.34 to 1.92 meq/L. [16] Table 3 represents the association of cord blood
magnesium concentration and the outcomes. Gestational age at delivery was associated with the
primary outcome of infant death by 1 year of age or moderate or severe cerebral palsy, as assessed at or
beyond 2 years of age, and various secondary outcomes. With every week increase in gestational age, the
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risk of primary outcome decreased by 6% (OR 0.94, 95% CI 0.92–0.96; p < 0.001). Additionally, female
gender was associated with lower odds of developing the primary outcome (OR 0.59, 95% CI 0.36–0.96;
p = 0.03). However, cord blood magnesium concentration was not associated with the primary outcome
(OR 0.95 (0.67, 1.36), p = 0.79), or any other secondary outcomes.
Table 2
Descriptive statistics of magnesium sulfate
concentration and administration
Mean ± SD
Cord blood Mg (meq/L)

2.98 ± 0.81

Total drug given (g)

39.3 ± 23.0

Time from dosing to birth (hr)

0.13 ± 0.60

Mg = magnesium; SD = standard deviation
Table 3
Association between cord blood magnesium level and neonatal/child outcomes
Adjusted Odds Ratio
(95% CI) #

P value

Primary composite outcome*

0.95 (0.67, 1.36)

0.79

Neonatal death

0.92 (0.62, 1.37)

0.67

Cerebral palsy

1.30 (0.69, 2.44)

0.42

Moderate to severe cerebral palsy

1.10 (0.53, 2.26)

0.80

Intraventricular hemorrhage

0.86 (0.65, 1.15)

0.31

Severe intraventricular hemorrhage

1.36 (0.57, 3.25)

0.49

Periventricular leukomalacia

0.58 (0.31, 1.10)

0.10

* A composite of infant death by 1 year of age or moderate or severe cerebral palsy, as assessed at or
beyond 2 years of age.
# Model adjusted for gestational age at birth and infant gender

Discussion
Our secondary analysis of the NICHD-MFMU network BEAM trial showed that cord blood magnesium
concentrations were not associated with moderate to severe cerebral palsy or neonatal death, or other
neurodevelopmental or neurosonographic outcomes. These results, along with the differing magnesium
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dosing regimens in the fetal neuroprotection trials, emphasize the need for additional research to discover
the ideal dosing scheme.
The majority of the controversy regarding the use of antenatal magnesium sulfate for the prevention of
cerebral palsy revolves around the lack of a significant difference in the primary outcomes of the three
largest RCTs and the different dosing schemes used in these, and other trials [4–6]. As stated in a 2009
clinical opinion, “the NICHD MFMU network trial took ten years and cost $25 million. It is, therefore,
unlikely that another, larger trial will ever be conducted [17].” If this is the case, it is increasingly important
to address the magnesium sulfate dosing regimen through the analysis of existing data. ACOG and
SMFM recommend developing specific guidelines for use in accordance with one of the more extensive
trials [9]. Identifying an optimal dosing scheme will help to clear up these vague recommendations.
Brookfield et al. [18] published a prospective pharmacokinetic study evaluating the profile of magnesium
sulfate in preeclamptic and non-preeclamptic women. Using the dosing regimen of a 4 g loading dose
and 2 g/hour maintenance dose, the steady-state concentration of magnesium sulfate was 7.2 mg/dL in
preeclamptic women compared with 5.1 mg/dL in non-preeclamptic women. The mean gestational age
of the women enrolled was 33.7 weeks of gestation, and 83% of them were preeclamptic. Using this
pharmacokinetic model, Brookfield et al. [19] applied it to the BEAM cohort. They concluded that a
maternal serum magnesium concentration between 3.7 and 4.4 mg/dL at delivery was associated with
the lowest probability of delivering an infant with cerebral palsy. It was also noted that the total
administered magnesium dose associated with the lowest probability of an infant developing cerebral
palsy was 64 g (95% CI 30 to 98). Methodological limitations were due to interruptions in dosing and
access to only the pre-pregnancy body mass index for covariate analysis. Limitations not discussed
consist of the decision to include women in both treatment and placebo arms in the analysis, and why a
maternal magnesium concentration above 4.4 mg/dL would confer a higher risk of delivering an infant
with cerebral palsy. The pharmacokinetics of umbilical cord magnesium sulfate concentrations were also
not investigated.
Initially, there were concerns regarding the safety of magnesium sulfate due to earlier findings of
increased neonatal mortality [20]. Subsequent studies and meta-analyses found this to be a false
association [3–8]. Our analysis confirms the lack of association between cord blood magnesium
concentrations and neonatal death. Additionally, maternal safety has been extensively studied, and there
is no significant difference in maternal deaths or major maternal adverse events between those exposed
to magnesium sulfate or not [3–6, 8].
The NICHD MFMU network BEAM trial has been the subject of multiple secondary analyses addressing
the relationship of magnesium sulfate dose, duration, or cord blood concentration with neonatal
outcomes as it is the largest trial performed to investigate the effect of magnesium sulfate on
neurodevelopmental outcomes and neonatal death [21–24]. Of note was a secondary analysis of the
BEAM trial, investigating whether magnesium cord blood concentration and magnesium sulfate infusion
at time of delivery are associated with cerebral palsy or death diagnosed by the age of 2 years [25]. Our
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analysis yielded comparable results to that study, demonstrating that there was no association between
magnesium cord blood concentration or magnesium sulfate infusion with cerebral palsy or death at the
time of delivery. However, the analysis by Palatnik el al [25]; included all non-anomalous singleton infants
whose mothers received magnesium sulfate, with only 509 (54%) mothers received magnesium sulfate at
the time of delivery. In our analysis, we included infants born to women who received magnesium sulfate
only within 6 hours of delivery. This was essential because of magnesium rapid renal elimination from
the maternal circulation. Also, we did not exclude twin gestations, as these are usually at higher risk of
cerebral palsy compared with singletons. In our analysis, clustering was adjusted for multiple gestation.
Additional analysis of the BEAM trial found that the duration of antenatal magnesium sulfate infusion is
not associated with stillbirth or neonatal death or cerebral palsy [22]. That cord blood magnesium
concentration was also not associated with delivery room resuscitation of neonates [23, 24].
Meta-analyses have found no change in rates of intraventricular hemorrhage, periventricular
leukomalacia, Apgar scores less than 7 at 5 minutes, neonatal seizures, and chronic lung disease
regardless of treatment (placebo vs. magnesium sulfate) [3, 8]. Our results found no association between
cord blood magnesium concentration and intraventricular hemorrhage or periventricular leukomalacia.
The sheer number of analyses addressing magnesium sulfate dosing, schedule, and effects, illuminates’
‘clinicians' desires to find evidence-based guidance for antenatal magnesium sulfate use for fetal
neuroprotection.
This is one of two studies only that investigate the relationship between cord blood magnesium
concentration and child death/neurodevelopmental outcomes. However, compared to the previous
secondary analysis [25] performed on the same data set, this study contains a larger number of neonates
(668 compared with 596) as it includes patients who received magnesium sulfate within 6 hours of
delivery and twin gestations. Also, we investigated additional outcomes such as abnormalities of
neonatal head ultrasound findings (intraventricular hemorrhage and periventricular leukomalacia). Cord
blood magnesium concentration is an accurate evaluation of the fetal magnesium concentration at the
time of birth. Of note, the original study was powered to determine a difference in the outcomes for
magnesium sulfate use versus control; it was not powered to detect a difference in the outcomes based
on cord blood magnesium concentration. This study only included patients from the primary RCT who
received magnesium sulfate, as we evaluated the association of cord blood magnesium concentrations
and the outcomes previously specified. However, our study has several limitations, including being a
retrospective analysis of a cohort from a prior conducted randomized trial, and a significant percentage
of missing data, which might have limited our ability to detect any differences.

Conclusions
In conclusion, cord blood magnesium concentrations were not significantly associated with moderate to
severe cerebral palsy or neonatal death, or other neurodevelopmental or sonographic outcomes. Further
research should involve pharmacokinetic and pharmacodynamic modeling to evaluate the relationship
between neonatal magnesium concentrations and child outcomes. This may be our best method to
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discover the ideal dose and schedule of magnesium sulfate for fetal neuroprotection, as it is unlikely that
another larger trial will ever be conducted.
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